Publications by Heidi Lyng

112 publications found

Publications 2024

1. Fackler MJ, Pleas M, Li Y, Soni A, Xing D, Cope L, Ali S, Van Le Q, Van Nguyen C, Pham HT, Duong LM, Vanden Berg E, Wadee R, Michelow P, Chen WC, Joffe M, Fjeldbo CS, Lyng H, Sukumar S (2024)
   Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries
   Clin Epigenetics, 16 (1), 56
   DOI 10.1186/s13148-024-01669-z, PubMed 38643219
2. Fernandez Salamanca M, Hompland T, Deręgowska-Cylke M, Van der Poel H, Bekers E, Guimaraes MAS, Lyng H, Van der Heide UA, Schoots IG, Van Houdt PJ (2024)
   A DWI-based hypoxia model shows robustness in an external prostatectomy cohort
   Front Oncol, 14, 1433197
   DOI 10.3389/fonc.2024.1433197, PubMed 39109282
3. Gorodetska I, Offermann A, Püschel J, Lukiyanchuk V, Gaete D, Kurzyukova A, Freytag V, Haider MT, Fjeldbo CS, Di Gaetano S, Schwarz FM, Patil S, Borkowetz A, Erb HHH, Baniahmad A, Mircetic J, Lyng H, Löck S, Linge A, Lange T, Knopf F, Wielockx B, Krause M, Perner S, Dubrovska A (2024)
   ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription
   Theranostics, 14 (2), 714-737
   DOI 10.7150/thno.88057, PubMed 38169509
4. Lukovic J, Pintilie M, Han K, Fyles AW, Bruce JP, Quevedo R, Pugh TJ, Fjeldbo CS, Lyng H, Milosevic MF (2024)
   An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for Cervical Cancer
   Clin Cancer Res, 30 (6), 1200-1207
   DOI 10.1158/1078-0432.CCR-23-2085, PubMed 38180733
5. Marsilla J, Weiss J, Ye XY, Welch M, Milosevic M, Lyng H, Hompland T, Bruheim K, Tadic T, Haibe-Kains B, Han K (2024)
   A T2-weighted MRI-based radiomic signature for disease-free survival in locally advanced cervical cancer following chemoradiation: An international, multicentre study
   Radiother Oncol, 199, 110463
   DOI 10.1016/j.radonc.2024.110463, PubMed 39067707
6. Skingen VE, Salberg UB, Hompland T, Fjeldbo CS, Helgeland H, Frikstad KM, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2024)
   Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer
   J Pathol, 264 (3), 270-283
   DOI 10.1002/path.6344, PubMed 39329425
7. Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H (2024)
   MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
   Radiother Oncol, 195, 110263
   DOI 10.1016/j.radonc.2024.110263, PubMed 38556173

Publications 2023

1. Leech M, Leijenaar RTH, Hompland T, Gaffney J, Lyng H, Marignol L (2023)
   Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring
   Anticancer Res, 43 (1), 351-357
   DOI 10.21873/anticanres.16170, PubMed 36585179
2. Skingen VE, Hompland T, Fjeldbo CS, Salberg UB, Helgeland H, Ragnum HB, Aarnes EK, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2023)
   Prostate cancer radiogenomics reveals proliferative gene expression programs associated with distinct MRI-based hypoxia levels
   Radiother Oncol, 188, 109875
   DOI 10.1016/j.radonc.2023.109875, PubMed 37640161

Publications 2022

1. Chakravarthy A, Reddin I, Henderson S, Dong C, Kirkwood N, Jeyakumar M, Rodriguez DR, Martinez NG, McDermott J, Su X, Egawa N, Fjeldbo CS, Skingen VE, Lyng H, Halle MK, Krakstad C, Soleiman A, Sprung S, Lechner M, Ellis PJI, Wass M, Michaelis M, Fiegl H, Salvesen H, Thomas GJ et al. (2022)
   Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance
   Nat Commun, 13 (1), 5818
   DOI 10.1038/s41467-022-33544-x, PubMed 36207323
2. Lyng H, Skipar K, Hompland T (2022)
   Targeted Therapy on the Screen: Do We Hit the Target?
   Clin Cancer Res, 28 (24), 5233-5234
   DOI 10.1158/1078-0432.CCR-22-2707, PubMed 36240006
3. Nilsen A, Hillestad T, Skingen VE, Aarnes EK, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H (2022)
   miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
   Mol Oncol, 16 (6), 1402-1419
   DOI 10.1002/1878-0261.13184, PubMed 35064630
4. Salberg UB, Skingen VE, Fjeldbo CS, Hompland T, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H (2022)
   A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients
   Br J Cancer, 127 (2), 321-328
   DOI 10.1038/s41416-022-01782-x, PubMed 35332267
5. Skipar K, Hompland T, Lund KV, Løndalen A, Malinen E, Kristensen GB, Lindemann K, Nakken ES, Bruheim K, Lyng H (2022)
   Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
   Radiother Oncol, 176, 17-24
   DOI 10.1016/j.radonc.2022.09.002, PubMed 36113778

Publications 2021

1. Hompland T, Fjeldbo CS, Lyng H (2021)
   Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
   Cancers (Basel), 13 (3)
   DOI 10.3390/cancers13030499, PubMed 33525508
2. Tulipan AJ, Salberg UB, Hole KH, Vlatkovic L, Aarnes EK, Revheim ME, Lyng H, Seierstad T (2021)
   Amino acid transporter expression and 18F-FACBC uptake at PET in primary prostate cancer
   Am J Nucl Med Mol Imaging, 11 (4), 250-259
   PubMed 34513278

Publications 2020

1. Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H (2020)
   Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
   EBioMedicine, 57, 102841
   DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139
2. Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, Lyng H (2020)
   MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
   Cancer Res, 80 (18), 3993-4003
   DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004

Publications 2019

1. Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H (2019)
   Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
   Neoplasia, 21 (4), 353-362
   DOI 10.1016/j.neo.2019.01.002, PubMed 30856376
2. Nilsen A, Jonsson M, Aarnes EK, Kristensen GB, Lyng H (2019)
   Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers
   Transl Oncol, 12 (3), 576-584
   DOI 10.1016/j.tranon.2018.12.010, PubMed 30660934
3. Pitman KE, Alluri SR, Kristian A, Aarnes EK, Lyng H, Riss PJ, Malinen E (2019)
   Influx rate of ¹⁸F-fluoroaminosuberic acid reflects cystine/glutamate antiporter expression in tumour xenografts
   Eur J Nucl Med Mol Imaging, 46 (10), 2190-2198
   DOI 10.1007/s00259-019-04375-8, PubMed 31264167
4. Switlyk MD, Salberg UB, Geier OM, Vlatkovic L, Lilleby W, Lyng H, Seierstad T (2019)
   PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings
   AJR Am J Roentgenol, 212 (6), 1206-1214
   DOI 10.2214/AJR.18.20743, PubMed 30888866

Publications 2018

1. Hompland T, Hole KH, Ragnum HB, Aarnes EK, Vlatkovic L, Lie AK, Patzke S, Brennhovd B, Seierstad T, Lyng H (2018)
   Combined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients
   Cancer Res, 78 (16), 4774-4785
   DOI 10.1158/0008-5472.CAN-17-3806, PubMed 29945958
2. Lam KC, Vyshenska D, Hu J, Rodrigues RR, Nilsen A, Zielke RA, Brown NS, Aarnes EK, Sikora AE, Shulzhenko N, Lyng H, Morgun A (2018)
   Transkingdom network reveals bacterial players associated with cervical cancer gene expression program
   PeerJ, 6, e5590
   DOI 10.7717/peerj.5590, PubMed 30294508
3. Leibfarth S, Winter RM, Lyng H, Zips D, Thorwarth D (2018)
   Potentials and challenges of diffusion-weighted magnetic resonance imaging in radiotherapy
   Clin Transl Radiat Oncol, 13, 29-37
   DOI 10.1016/j.ctro.2018.09.002, PubMed 30294681
4. Mikalsen SG, Mikalsen LTG, Sandvik JA, Aarnes EK, Fenne S, Flatmark K, Lyng H, Edin NFJ, Pettersen EO (2018)
   Low dose-rate irradiation with [³H]-labelled valine to selectively target hypoxic cells in a human colorectal cancer xenograft model
   Acta Oncol, 57 (9), 1216-1224
   DOI 10.1080/0284186X.2018.1457223, PubMed 29630428

Publications 2017

1. Li AN, Andersen E, Lervag C, Julin CH, Lyng H, Hellebust TP, Malinen E (2017)
   Dynamic contrast enhanced magnetic resonance imaging for hypoxia mapping and potential for brachytherapy targeting
   Phys. Imag. Radiat. Oncol., 2, 1-6
   DOI 10.1016/j.phro.2017.03.002
2. Lyng H, Malinen E (2017)
   Hypoxia in cervical cancer: from biology to imaging
   Clin Transl Imaging, 5 (4), 373-388
   DOI 10.1007/s40336-017-0238-7, PubMed 28804704
3. Torheim T, Malinen E, Hole KH, Lund KV, Indahl UG, Lyng H, Kvaal K, Futsaether CM (2017)
   Autodelineation of cervical cancers using multiparametric magnetic resonance imaging and machine learning
   Acta Oncol, 56 (6), 806-812
   DOI 10.1080/0284186X.2017.1285499, PubMed 28464746

Publications 2016

1. Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H (2016)
   Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
   Clin Cancer Res, 22 (16), 4067-76
   DOI 10.1158/1078-0432.CCR-15-2322, PubMed 27012812
2. Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H (2016)
   Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
   PLoS One, 11 (5), e0156259
   DOI 10.1371/journal.pone.0156259, PubMed 27244197
3. Hasvold G, Lund-Andersen C, Lando M, Patzke S, Hauge S, Suo Z, Lyng H, Syljuåsen RG (2016)
   Hypoxia-induced alterations of G2 checkpoint regulators
   Mol Oncol, 10 (5), 764-73
   DOI 10.1016/j.molonc.2015.12.015, PubMed 26791779
4. Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
   Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
   Br J Cancer, 115 (8), 929-939
   DOI 10.1038/bjc.2016.278, PubMed 27599042
5. Torheim T, Groendahl AR, Andersen EK, Lyng H, Malinen E, Kvaal K, Futsaether CM (2016)
   Cluster analysis of dynamic contrast enhanced MRI reveals tumor subregions related to locoregional relapse for cervical cancer patients
   Acta Oncol, 55 (11), 1294-1298
   DOI 10.1080/0284186X.2016.1189091, PubMed 27564398
6. Wilting SM, Miok V, Jaspers A, Boon D, Sørgård H, Lando M, Snoek BC, van Wieringen WN, Meijer CJ, Lyng H, Snijders PJ, Steenbergen RD (2016)
   Aberrant methylation-mediated silencing of microRNAs contributes to HPV-induced anchorage independence
   Oncotarget, 7 (28), 43805-43819
   DOI 10.18632/oncotarget.9698, PubMed 27270309

Publications 2015

1. Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H (2015)
   Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
   Epigenetics, 10 (10), 970-80
   DOI 10.1080/15592294.2015.1085140, PubMed 26291246

Publications 2014

1. Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
   Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
   J Enzyme Inhib Med Chem, 30 (5), 689-721
   DOI 10.3109/14756366.2014.966704, PubMed 25347767
2. Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad KM, Hole KH, Seierstad T, Lyng H (2014)
   The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
   Br J Cancer, 112 (2), 382-90
   DOI 10.1038/bjc.2014.604, PubMed 25461803
3. Shulzhenko N, Lyng H, Sanson GF, Morgun A (2014)
   Ménage à trois: an evolutionary interplay between human papillomavirus, a tumor, and a woman
   Trends Microbiol, 22 (6), 345-53
   DOI 10.1016/j.tim.2014.02.009, PubMed 24674660
4. Torheim T, Malinen E, Kvaal K, Lyng H, Indahl UG, Andersen EK, Futsaether CM (2014)
   Classification of dynamic contrast enhanced MR images of cervical cancers using texture analysis and support vector machines
   IEEE Trans Med Imaging, 33 (8), 1648-56
   DOI 10.1109/TMI.2014.2321024, PubMed 24802069

Publications 2013

1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2013)
   Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
   Radiother Oncol, 107 (1), 117-22
   DOI 10.1016/j.radonc.2012.11.007, PubMed 23333024
2. Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, Kristensen GB, Steenbergen RD, Lyng H (2013)
   Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
   J Pathol, 230 (1), 59-69
   DOI 10.1002/path.4168, PubMed 23335387
3. Mine KL, Shulzhenko N, Yambartsev A, Rochman M, Sanson GF, Lando M, Varma S, Skinner J, Volfovsky N, Deng T, Brenna SM, Carvalho CR, Ribalta JC, Bustin M, Matzinger P, Silva ID, Lyng H, Gerbase-DeLima M, Morgun A (2013)
   Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer
   Nat Commun, 4, 1806
   DOI 10.1038/ncomms2693, PubMed 23651994
4. Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
   Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
   Int J Radiat Oncol Biol Phys, 87 (4), 753-60
   DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332

Publications 2012

1. Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuåsen RG, Sundfør K, Kristensen GB, Holm R, Malinen E, Lyng H (2012)
   Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
   Cancer Res, 72 (20), 5285-95
   DOI 10.1158/0008-5472.CAN-12-1085, PubMed 22890239
2. Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR (2012)
   Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
   Radiat Oncol, 7, 75
   DOI 10.1186/1748-717X-7-75, PubMed 22621752

Publications 2011

1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2011)
   Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
   Int J Radiat Oncol Biol Phys, 82 (3), e485-92
   DOI 10.1016/j.ijrobp.2011.05.050, PubMed 22014954
2. Andersen EK, Kristensen GB, Lyng H, Malinen E (2011)
   Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers
   Acta Oncol, 50 (6), 859-65
   DOI 10.3109/0284186X.2011.578586, PubMed 21767185
3. Bergersen LC, Glad IK, Lyng H (2011)
   Weighted lasso with data integration
   Stat Appl Genet Mol Biol, 10 (1)
   DOI 10.2202/1544-6115.1703, PubMed 23089821
4. Halle C, Lando M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
   Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
   Radiother Oncol, 101 (1), 152-7
   DOI 10.1016/j.radonc.2011.05.052, PubMed 21680035
5. Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
   Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
   Clin Cancer Res, 17 (16), 5501-12
   DOI 10.1158/1078-0432.CCR-11-0297, PubMed 21737508
6. Landsverk KS, Patzke S, Rein ID, Stokke C, Lyng H, De Angelis PM, Stokke T (2011)
   Three independent mechanisms for arrest in G2 after ionizing radiation
   Cell Cycle, 10 (5), 819-29
   DOI 10.4161/cc.10.5.14968, PubMed 21325885

Publications 2009

1. Holm R, Ali T, Svendsrud DH, Nesland JM, Kristensen GB, Lyng H (2009)
   Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome
   Oncol Rep, 22 (1), 11-5
   DOI 10.3892/or_00000399, PubMed 19513498
2. Lando M, Holden M, Bergersen LC, Svendsrud DH, Stokke T, Sundfør K, Glad IK, Kristensen GB, Lyng H (2009)
   Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer
   PLoS Genet, 5 (11), e1000719
   DOI 10.1371/journal.pgen.1000719, PubMed 19911042

Publications 2008

1. Ferkingstad E, Frigessi A, Lyng H (2008)
   Indirect genomic effects on survival from gene expression data
   Genome Biol, 9 (3), R58
   DOI 10.1186/gb-2008-9-3-r58, PubMed 18358079
2. Holm R, Kraus I, Skomedal H, Langerød A, Kristensen GB, Lyng H (2008)
   Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma
   Open Virol J, 2, 74-81
   DOI 10.2174/1874357900802010074, PubMed 19440467
3. Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
   GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
   Genome Biol, 9 (5), R86
   DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990
4. Nygaard V, Liu F, Holden M, Kuo WP, Trimarchi J, Ohno-Machado L, Cepko CL, Frigessi A, Glad IK, Wiel MA, Hovig E, Lyng H (2008)
   Validation of oligoarrays for quantitative exploration of the transcriptome
   BMC Genomics, 9, 258
   DOI 10.1186/1471-2164-9-258, PubMed 18513391

Publications 2007

1. Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfør K, Kristensen GB, Gribbestad IS (2007)
   Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas
   BMC Cancer, 7, 11
   DOI 10.1186/1471-2407-7-11, PubMed 17233882

Publications 2006

1. Lyng H, Brøvig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, Oksefjell H, Sundfør K, Kristensen GB, Stokke T (2006)
   Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
   BMC Genomics, 7, 268
   DOI 10.1186/1471-2164-7-268, PubMed 17054779

Publications 2005

1. Frigessi A, van de Wiel MA, Holden M, Svendsrud DH, Glad IK, Lyng H (2005)
   Genome-wide estimation of transcript concentrations from spotted cDNA microarray data
   Nucleic Acids Res, 33 (17), e143
   DOI 10.1093/nar/gni141, PubMed 16204447
2. Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T (2005)
   Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype
   Int J Cancer, 115 (6), 935-42
   DOI 10.1002/ijc.20962, PubMed 15723354
3. Scheel I, Aldrin M, Glad IK, Sørum R, Lyng H, Frigessi A (2005)
   The influence of missing value imputation on detection of differentially expressed genes from microarray data
   Bioinformatics, 21 (23), 4272-9
   DOI 10.1093/bioinformatics/bti708, PubMed 16216830

Publications 2004

1. Landsverk KS, Lyng H, Stokke T (2004)
   The response of malignant B lymphocytes to ionizing radiation: cell cycle arrest, apoptosis and protection against the cytotoxic effects of the mitotic inhibitor nocodazole
   Radiat Res, 162 (4), 405-15
   DOI 10.1667/rr3235, PubMed 15447042
2. Lyng H, Badiee A, Svendsrud DH, Hovig E, Myklebost O, Stokke T (2004)
   Profound influence of microarray scanner characteristics on gene expression ratios: analysis and procedure for correction
   BMC Genomics, 5 (1), 10
   DOI 10.1186/1471-2164-5-10, PubMed 15018648
3. Lyng H, Beigi M, Svendsrud DH, Brustugun OT, Stokke T, Kristensen GB, Sundfør K, Skjønsberg A, De Angelis PM (2004)
   Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix
   Int J Cancer, 111 (3), 358-66
   DOI 10.1002/ijc.20258, PubMed 15221962

Publications 2001

1. Lyng H, Sundfor K, Rofstad EK (2001)
   Serial changes in tumor oxygenation during the early phase of radiation therapy in cervical cancer - Are we quantitating hypoxia change? Response
   Int. J. Radiat. Oncol. Biol. Phys., 49 (1), 285-289
   DOI 10.1016/S0360-3016(00)00795-1
2. Lyng H, Vorren AO, Sundfør K, Taksdal I, Lien HH, Kaalhus O, Rofstad EK (2001)
   Intra- and intertumor heterogeneity in blood perfusion of human cervical cancer before treatment and after radiotherapy
   Int J Cancer, 96 (3), 182-90
   DOI 10.1002/ijc.1019, PubMed 11410887
3. Lyng H, Vorren AO, Sundfør K, Taksdal I, Lien HH, Kaalhus O, Rofstad EK (2001)
   Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging
   J Magn Reson Imaging, 14 (6), 750-6
   DOI 10.1002/jmri.10016, PubMed 11747032
4. Måseide K, Lyng H, Rofstad EK (2001)
   Microvessel oxyhemoglobin saturation does not reflect tissue oxygen tension in human melanoma xenografts
   Microvasc Res, 61 (2), 199-202
   DOI 10.1006/mvre.2000.2294, PubMed 11254399

Publications 2000

1. Bjørnaes I, Lyng H, Dahle GA, Kaalhus O, Rofstad EK (2000)
   Intratumor heterogeneity in perfusion in human melanoma xenografts measured by contrast-enhanced magnetic resonance imaging
   Magn Reson Imaging, 18 (8), 997-1002
   DOI 10.1016/s0730-725x(00)00188-0, PubMed 11121704
2. Lyng H, Haraldseth O, Rofstad EK (2000)
   Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging
   Magn Reson Med, 43 (6), 828-36
   DOI 10.1002/1522-2594(200006)43:6<828::aid-mrm8>3.0.co;2-p, PubMed 10861877
3. Lyng H, Sundfør K, Rofstad EK (2000)
   Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis
   Int J Radiat Oncol Biol Phys, 46 (4), 935-46
   DOI 10.1016/s0360-3016(99)00497-6, PubMed 10705016
4. Lyng H, Sundfør K, Tropé C, Rofstad EK (2000)
   Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy
   Clin Cancer Res, 6 (3), 1104-12
   PubMed 10741740
5. Rofstad EK, Sundfør K, Lyng H, Tropé CG (2000)
   Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis
   Br J Cancer, 83 (3), 354-9
   DOI 10.1054/bjoc.2000.1266, PubMed 10917551
6. Sundfør K, Lyng H, Tropé CG, Rofstad EK (2000)
   Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization
   Radiother Oncol, 54 (2), 101-7
   DOI 10.1016/s0167-8140(99)00175-9, PubMed 10699471

Publications 1999

1. Lyng H, Tanum G, Evensen JF, Rofstad EK (1999)
   Changes in oxygen tension during radiotherapy of head and neck tumours
   Acta Oncol, 38 (8), 1037-42
   DOI 10.1080/028418699432329, PubMed 10665759
2. Olsen G, Lyng H, Tufto I, Solberg K, Bjørnaes I, Rofstad EK (1999)
   Measurement of proliferation activity in human melanoma xenografts by magnetic resonance imaging
   Magn Reson Imaging, 17 (3), 393-402
   DOI 10.1016/s0730-725x(98)00175-1, PubMed 10195582

Publications 1998

1. Lyng H, Dahle GA, Kaalhus O, Skretting A, Rofstad EK (1998)
   Measurement of perfusion rate in human melanoma xenografts by contrast-enhanced magnetic resonance imaging
   Magn Reson Med, 40 (1), 89-98
   DOI 10.1002/mrm.1910400113, PubMed 9660558
2. Lyng H, Sundfor K, Rofstad EK (1998)
   Oxygen tension and not vascular density or apoptosis predicts for metastasis in human cervix carcinoma
   20TH EUROPEAN CONFERENCE ON MICROCIRCULATION, 13-17
3. Lyng H, Sundfør K, Rofstad EK (1998)
   Oxygen tension in human squamous cell carcinoma and adenocarcinoma of the uterine cervix
   Adv Exp Med Biol, 454, 635-41
   DOI 10.1007/978-1-4615-4863-8_75, PubMed 9889944
4. Sundfør K, Lyng H, Rofstad EK (1998)
   Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix
   Br J Cancer, 78 (6), 822-7
   DOI 10.1038/bjc.1998.586, PubMed 9743308
5. Sundfør K, Lyng H, Rofstad EK (1998)
   Oxygen tension and vascular density in adenocarcinoma and squamous cell carcinoma of the uterine cervix
   Acta Oncol, 37 (7-8), 665-70
   DOI 10.1080/028418698430016, PubMed 10050984
6. Tufto I, Lyng H, Rofstad EK (1998)
   Vascular density in human melanoma xenografts: relationship to angiogenesis, perfusion and necrosis
   Cancer Lett, 123 (2), 159-65
   DOI 10.1016/s0304-3835(97)00424-2, PubMed 9489483

Publications 1997

1. Lyng H, Sundfør K, Rofstad EK (1997)
   Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia
   Radiother Oncol, 44 (2), 163-9
   DOI 10.1016/s0167-8140(97)01920-8, PubMed 9288845
2. Lyng H, Sundfør K, Tanum G, Rofstad EK (1997)
   Oxygen tension in primary tumours of the uterine cervix and lymph node metastases of the head and neck
   Adv Exp Med Biol, 428, 55-60
   DOI 10.1007/978-1-4615-5399-1_9, PubMed 9500029
3. Lyng H, Tufto I, Skretting A, Rofstad EK (1997)
   Proton relaxation times and interstitial fluid pressure in human melanoma xenografts
   Br J Cancer, 75 (2), 180-3
   DOI 10.1038/bjc.1997.30, PubMed 9010023
4. Sundfør K, Lyng H, Kongsgård UL, Tropé C, Rofstad EK (1997)
   Polarographic measurement of pO2 in cervix carcinoma
   Gynecol Oncol, 64 (2), 230-6
   DOI 10.1006/gyno.1996.4571, PubMed 9038268
5. Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, Mueller-Klieser W (1997)
   Correlation of high lactate levels in head and neck tumors with incidence of metastasis
   Am J Pathol, 150 (2), 409-15
   PubMed 9033256

Publications 1996

1. Lyng H, Sundfør K, Tropé C, Rofstad EK (1996)
   Oxygen tension and vascular density in human cervix carcinoma
   Br J Cancer, 74 (10), 1559-63
   DOI 10.1038/bjc.1996.589, PubMed 8932335
2. Rofstad EK, Eide K, Skøyum R, Hystad ME, Lyng H (1996)
   Apoptosis, energy metabolism, and fraction of radiobiologically hypoxic cells: a study of human melanoma multicellular spheroids
   Int J Radiat Biol, 70 (3), 241-9
   DOI 10.1080/095530096144978, PubMed 8800195
3. Rofstad EK, Johnsen NM, Lyng H (1996)
   Hypoxia-induced tetraploidisation of a diploid human melanoma cell line in vitro
   Br J Cancer Suppl, 27, S136-9
   PubMed 8763866
4. Rofstad EK, Lyng H (1996)
   Xenograft model systems for human melanoma
   Mol Med Today, 2 (9), 394-403
   DOI 10.1016/s1357-4310(96)10035-6, PubMed 8885259
5. Tufto I, Lyng H, Rofstad EK (1996)
   Interstitial fluid pressure, perfusion rate and oxygen tension in human melanoma xenografts
   Br J Cancer Suppl, 27, S252-5
   PubMed 8763891

Publications 1995

1. Jakobsen I, Kaalhus O, Lyng H, Rofstad EK (1995)
   Detection of necrosis in human tumour xenografts by proton magnetic resonance imaging
   Br J Cancer, 71 (3), 456-61
   DOI 10.1038/bjc.1995.93, PubMed 7880724
2. Jakobsen I, Lyng H, Kaalhus O, Rofstad EK (1995)
   MRI of human tumor xenografts in vivo: proton relaxation times and extracellular tumor volume
   Magn Reson Imaging, 13 (5), 693-700
   DOI 10.1016/0730-725x(95)00019-d, PubMed 8569443
3. Lyng H, Olsen DR, Petersen SB, Rofstad EK (1995)
   31P NMR spectroscopy studies of phospholipid metabolism in human melanoma xenograft lines differing in rate of tumour cell proliferation
   NMR Biomed, 8 (2), 65-71
   DOI 10.1002/nbm.1940080204, PubMed 7547188
4. Lyng H, Rofstad EK (1995)
   Treatment failure following sequential thermoradiotherapy of locally advanced breast carcinoma occurs primarily in poorly vascularized tumors
   Oncology, 52 (6), 443-7
   DOI 10.1159/000227508, PubMed 7478428
5. Olsen DR, Lyng H, Petersen S, Rofstad EK (1995)
   Spin-lattice relaxation time of inorganic phosphate in human tumor xenografts measured in vivo by 31P-magnetic resonance spectroscopy. Influence of oxygen tension
   Acta Oncol, 34 (3), 339-43
   DOI 10.3109/02841869509093986, PubMed 7779420
6. Olsen DR, Lyng H, Petersen SB, Rofstad EK (1995)
   Effect of melanin on phosphorus T1S in human melanoma xenografts studied by 31P MRS
   Magn Reson Imaging, 13 (6), 847-52
   DOI 10.1016/0730-725x(95)00054-k, PubMed 8544656

Publications 1994

1. Olsen DR, Lyng H, Southon TE, Rofstad EK (1994)
   31P-nuclear magnetic resonance spectroscopy in vivo of four human melanoma xenograft lines: spin-lattice relaxation times
   Radiother Oncol, 32 (1), 54-62
   DOI 10.1016/0167-8140(94)90449-9, PubMed 7938679
2. Rofstad EK, Lyng H, Olsen DR, Steinsland E (1994)
   Non-invasive assessment of tumor oxygenation status by integrated 31P NMR spectroscopy and 1H NMR imaging
   Adv Exp Med Biol, 345, 531-8
   DOI 10.1007/978-1-4615-2468-7_71, PubMed 8079755
3. Rofstad EK, Steinsland E, Kaalhus O, Chang YB, Høvik B, Lyng H (1994)
   Magnetic resonance imaging of human melanoma xenografts in vivo: proton spin-lattice and spin-spin relaxation times versus fractional tumour water content and fraction of necrotic tumour tissue
   Int J Radiat Biol, 65 (3), 387-401
   DOI 10.1080/09553009414550451, PubMed 7908318

Publications 1993

1. Lyng H, Monge OR, Sager EM, Rofstad EK (1993)
   Prediction of treatment temperatures in clinical hyperthermia of locally advanced breast carcinoma: the use of contrast enhanced computed tomography
   Int J Radiat Oncol Biol Phys, 26 (3), 451-7
   DOI 10.1016/0360-3016(93)90963-v, PubMed 8390419
2. Lyng H, Olsen DR, Southon TE, Rofstad EK (1993)
   31P-nuclear magnetic resonance spectroscopy in vivo of six human melanoma xenograft lines: tumour bioenergetic status and blood supply
   Br J Cancer, 68 (6), 1061-70
   DOI 10.1038/bjc.1993.483, PubMed 8260356
3. Lyng H, Rofstad EK (1993)
   Thermal dose and secondary tumour cell death
   Int J Hyperthermia, 9 (5), 755-61
   DOI 10.3109/02656739309032062, PubMed 8245585

Publications 1992

1. Lyng H, Skretting A, Rofstad EK (1992)
   Blood flow in six human melanoma xenograft lines with different growth characteristics
   Cancer Res, 52 (3), 584-92
   PubMed 1732046

Publications 1991

1. Lyng H, Monge OR, Bøhler PJ, Rofstad EK (1991)
   Temperature distribution in locally advanced breast carcinoma during hyperthermic treatment: relationship to perfusion, vascular density, and histology
   Int J Radiat Oncol Biol Phys, 21 (2), 423-30
   DOI 10.1016/0360-3016(91)90791-2, PubMed 1648045
2. Lyng H, Monge OR, Bøhler PJ, Rofstad EK (1991)
   Changes in temperatures and thermal doses with fraction number during hyperthermic treatment of locally advanced breast carcinoma
   Int J Hyperthermia, 7 (6), 815-25
   DOI 10.3109/02656739109056450, PubMed 1666900
3. Lyng H, Monge OR, Bøhler PJ, Rofstad EK (1991)
   The relevance of tumour and surrounding normal tissue vascular density in clinical hyperthermia of locally advanced breast carcinoma
   Int J Radiat Biol, 60 (1-2), 189-93
   DOI 10.1080/09553009114551821, PubMed 1677970
4. Lyng H, Monge OR, Bøhler PJ, Rofstad EK (1991)
   Relationships between thermal dose and heat-induced tissue and vascular damage after thermoradiotherapy of locally advanced breast carcinoma
   Int J Hyperthermia, 7 (3), 403-15
   DOI 10.3109/02656739109005006, PubMed 1919137

Publications 1990

1. Monge OR, Lindsköld L, Lyng H, Sager EM (1990)
   Positioning of temperature measurement points using multiplanar computed tomography
   Int J Hyperthermia, 6 (5), 957-60
   DOI 10.3109/02656739009140977, PubMed 2250121